

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5463077

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JAN DELABIE	04/02/2019
ERLEND B. SMELAND	03/27/2019
RECEIVING PARTY DATA	
Name:	OSLO UNIVERSITY HOSPITAL HF
Street Address:	TÅRNBYGGET, KIRKEVEIEN 166
City:	OSLO
State/Country:	NORWAY
Postal Code:	0450
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16094965
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-616-5600
Email:	assignments@leydig.com
Correspondent Name:	LEYDIG, VOIT & MAYER, LTD.
Address Line 1:	TWO PRUDENTIAL PLAZA, SUITE 4900
Address Line 2:	180 NORTH STETSON AVENUE
Address Line 4:	CHICAGO, ILLINOIS 60601-6731
ATTORNEY DOCKET NUMBER:	740542
NAME OF SUBMITTER:	CHERYL BELCIK
SIGNATURE:	/Cheryl Belcik/
DATE SIGNED:	04/08/2019
Total Attachments: 6	
source=Assignment-Olso-740542#page1.tif	
source=Assignment-Olso-740542#page2.tif	
source=Assignment-Olso-740542#page3.tif	
source=Assignment-Olso-740542#page4.tif	

source=Assignment-Olso-740542#page5.tif

source=Assignment-Olso-740542#page6.tif

ASSIGNMENT

WHEREAS, WE

(1), Jan Delabie, and

(2) Erlend B. Smeland,

hereinafter referred to as Assignor, have co-invented a certain invention entitled:

EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO

for which invention an application (non-provisional) for a U.S. patent was filed on October 19, 2018, under U.S. Application No. 16/094,965, and

WHEREAS, we are some of the inventors named in the above-referenced patent application,

WHEREAS, Oslo University Hospital HF, Tårnbygget, Kirkeveien 166, 0450 Oslo, Norway, hereinafter referred to as Assignee, is desirous of acquiring our entire right, title, and interest in, to, and under the invention described in the patent application, including our entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee our entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such

In re Appln. of Staudt et al.
Attorney Docket No. 740542

additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,


Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set their hand on the date shown below.

Date April 2, 2019




Jan Delabie

Date April 2, 19



Witness:

Date April 2, 19



Witness:

In re Appln. of Staudt et al.
Attorney Docket No. 740542

Date _____

Erlend B. Smeland

Date _____

Witness:

Date _____

Witness:

=====

ASSIGNMENT

WHEREAS, WE

(1), Jan Delabie, and

(2) Erlend B. Smeland,

hereinafter referred to as Assignor, have co-invented a certain invention entitled:

EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO

for which invention an application (non-provisional) for a U.S. patent was filed on October 19, 2018, under U.S. Application No. 16/094,965, and

WHEREAS, we are some of the inventors named in the above-referenced patent application,

WHEREAS, Oslo University Hospital HF, Tårnbygget, Kirkeveien 166, 0450 Oslo, Norway, hereinafter referred to as Assignee, is desirous of acquiring our entire right, title, and interest in, to, and under the invention described in the patent application, including our entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee our entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

In re Appln. of Staudt et al.
Attorney Docket No. 740542

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set their hand on the date shown below.

Date _____

Jan Delabie

Date _____


Witness:

Date _____

Witness:


In re Appln. of Staudt et al.
Attorney Docket No. 740542

Date March 27th 2019




Erlend B. Smeland

Date March 27th 2019



Witness:

Date March 28th 2019



Witness:

=====